ArticleClinical and molecular hepatology2024
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression.
Article in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- The application of artificial intelligence in the intersection of metabolic dysfunction-associated steatotic liver disease and cardiovascular diseases.Frontiers in immunology · 2026Review
- Developmental programming: Differing impact of prenatal testosterone and prenatal bisphenol-A -treatment on hepatic methylome in female sheep.Molecular and cellular endocrinology · 2025Article
- Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.Journal of gastroenterology · 2025Article
- PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".Clinical and molecular hepatology · 2025Article
- Correspondence to editorial on "DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease".Clinical and molecular hepatology · 2025Article
- Biological and clinical role of TREM2 in liver diseases.Hepatology communications · 2024Review
- Correspondence to editorial on "Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma".Clinical and molecular hepatology · 2024Article
- The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective.Clinical and molecular hepatology · 2024Article
- Correspondence on Editorial regarding "Identification of signature gene set as highly accurate determination of MASLD progression".Clinical and molecular hepatology · 2024Article
- Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.Frontiers in immunology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis and liver cancer, steatosis and MASH must be distinguished during patient treatment. Here, we investigate the genomes, epigenomes, and transcriptomes of MASLD patients to identify signature gene set for more accurate tracking of MASLD progression.
methodsBiopsy-tissue and blood samples from patients with 134 MASLD, comprising 60 steatosis and 74 MASH patients were performed omics analysis. SVM learning algorithm were used to calculate most predictive features. Linear regression was applied to find signature gene set that distinguish the stage of MASLD and to validate their application into independent cohort of MASLD.
resultsAfter performing WGS, WES, WGBS, and total RNA-seq on 134 biopsy samples from confirmed MASLD patients, we provided 1,955 MASLD-associated features, out of 3,176 somatic variant callings, 58 DMRs, and 1,393 DEGs that track MASLD progression. Then, we used a SVM learning algorithm to analyze the data and select the most predictive features. Using linear regression, we identified a signature gene set capable of differentiating the various stages of MASLD and verified it in different independent cohorts of MASLD and a liver cancer cohort.
conclusionWe identified a signature gene set (i.e., CAPG, HYAL3, WIPI1, TREM2, SPP1, and RNASE6) with strong potential as a panel of diagnostic genes of MASLD-associated disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.